← Leaderboards
Karina Serban
National Jewish Health
$2,991,972
Attributed
$2,991,972
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,991,972 · 2
By mechanism
R01$2,198,712 · 1
K08$793,260 · 1
Top collaborators
No co-investigators on record.
Most similar at National Jewish Health
Same institution · by research overlap
- Peter M Henson$23,575,855
- Susan M Majka$13,999,914
- Hong W Chu$18,238,701
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoMasp2 GeneDepositionInflammationLung InjuryMannose Binding LectinCell InjuryComplement PathwayClinically RelevantExposure To Cigarette SmokeLectinLungCigarette Smoke-Induced Lung InjuryCigarette SmokingBindingBiological MarkersComplementComplement ActivationCellsCigarette SmokeEnsureEpithelial CellsCigarette Smoke-InducedMeasurement
Grant awards (8)
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema$701,802
R01 · FY2025 · HL · contact PI
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema$760,358
R01 · FY2023 · HL · contact PI
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema$736,552
R01 · FY2023 · HL · contact PI
Mannose binding lectin-dependent complement activation in emphysema$158,652
K08 · FY2023 · HL · contact PI
Mannose binding lectin-dependent complement activation in emphysema$158,652
K08 · FY2022 · HL · contact PI
Mannose binding lectin-dependent complement activation in emphysema$158,652
K08 · FY2021 · HL · contact PI
Mannose binding lectin-dependent complement activation in emphysema$158,652
K08 · FY2020 · HL · contact PI
Mannose binding lectin-dependent complement activation in emphysema$158,652
K08 · FY2019 · HL · contact PI